Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 3:2018:2640674.
doi: 10.1155/2018/2640674. eCollection 2018.

Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing's Sarcoma: A Systematic Review

Pavan Tenneti  1 , Umar Zahid  2 , Ahmad Iftikhar  3 , Seongseok Yun  4 , Atif Sohail  3 , Zabih Warraich  3 , Faiz Anwer  3
Affiliations
Review

Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing's Sarcoma: A Systematic Review

Pavan Tenneti et al. Sarcoma. .

Abstract

Background: Relapsed Ewing's sarcoma (RES) is an aggressive malignancy with poor survival. Although high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) given after conventional chemotherapy (CC) has shown survival benefits, it is not generally used in the United States for RES. We performed a systemic review to evaluate the benefits of HDCT for RES.

Methods: Literature search involved Medline, Embase, and Cochrane database. We included studies with RES patients treated with HDCT/ASCT.

Results: Twenty-four studies with total of 345 reported RES patients that got HDCT were included in final analysis. Seventeen studies had patients with multiple malignancies including RES, while seven had only RES patients. At 2 and 3-5 years, event-free survival (EFS) in studies with only RES patients ranged 42-47% and 20-61% and overall survival (OS) ranged 50-66% and 33-77%, respectively. In studies with combined patients that reported outcomes of RES separately, the EFS at 1-3 and 4 years was 36-66% and 17-50%, respectively. The OS at 1-2 and 3-4 years was 40-60% and 50-70%.

Conclusions: Most studies using HDCT/ASCT as consolidation regimen showed improved survival benefits compared to CC. Randomized controlled studies are needed to determine true clinical benefits of HDCT followed by ASCT in patients with RES.

PubMed Disclaimer

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Paulussen M., Bielack S., Jurgens H., et al. Ewing’s sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology. 2009;20(4):140–142. doi: 10.1093/annonc/mdp155. - DOI - PubMed
    1. Stahl M., Ranft A., Paulussen M., et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatric Blood and Cancer. 2011;57(4):549–553. doi: 10.1002/pbc.23040. - DOI - PubMed
    1. Bacci G., Ferrari S., Longhi A., et al. Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Annals of Oncology. 2003;14(11):1654–1659. doi: 10.1093/annonc/mdg457. - DOI - PubMed
    1. Leavey P. J., Mascarenhas L., Marina N., et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children’s Oncology Group. Pediatric Blood and Cancer. 2008;51(3):334–338. doi: 10.1002/pbc.21618. - DOI - PMC - PubMed
    1. Rodriguez-Galindo C., Billups C. A., Kun L. E., et al. Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979-1999. Cancer. 2002;94(2):561–569. doi: 10.1002/cncr.10192. - DOI - PubMed

LinkOut - more resources